Collegium Pharma (COLL) Misses Q2 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Collegium Reports Second Quarter Financial Results and Provides Corporate Update
August 12, 2015 5:00 PM EDTCANTON, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the second quarter of 2015 and provided a corporate update.
Michael Heffernan, Collegium's Chairman and CEO, stated, "During the second quarter, Collegium achieved a number of important milestones. The successful completion of our IPO in May 2015 provides us with substantial additional resources to launch Xtampza ER pending final approval by the FDA and to move another product candidate into the clinic. Additionally, the commercial team has made significant progress in preparing for a potential 2016 launch of... More
Collegium Reports Second Quarter Financial Results and Provides Corporate Update
August 12, 2015 5:00 PM EDTCANTON, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the second quarter of 2015 and provided a corporate update.
Michael Heffernan, Collegium's Chairman and CEO, stated, "During the second quarter, Collegium achieved a number of important milestones. The successful completion of our IPO in May 2015 provides us with substantial additional resources to launch Xtampza ER pending final approval by the FDA and to move another product candidate into the clinic. Additionally, the commercial team has made significant progress in preparing for a potential 2016 launch of... More
